Searching for your content…
In-Language News
Contact Us
888-776-0942
from 8 AM – 10 PM ET
News provided by
Apr 19, 2022, 07:30 ET
Share this article
Theralink currently supports preclinical and clinical studies across 18 biopharma clients, including multinational corporations
Ongoing discussions with existing clients for development of Companion Diagnostics, a large global market for oncology precision medicine
DENVER, April 19, 2022 /PRNewswire/ — Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision medicine company with a novel phosphoprotein-based assay for breast cancer, today announced that it has significantly expanded the adoption of its Laser Capture Microdissection (LCM) and Reverse Phase Protein Array (RPPA) precision medicine technology to biopharmaceutical companies, including multinational healthcare corporations. The Company has supported 41 preclinical and clinical studies for 18 biopharma companies and is currently undergoing discussions to develop Companion Diagnostics (CDx) with several of its existing clients.
Mick Ruxin, M.D., President & CEO of Theralink Technologies, said, "We have partnered with some of the largest and most innovative global biopharma companies, driven by the unique value of our patented phosphoprotein precision medicine technology and our dedicated Theralink team of experts. I am encouraged by the rapid uptake of our biopharma offerings and excited by the significant market potential to develop Companion Diagnostics–tests required for oncologists to prescribe targeted drug therapy. We look forward to further expanding our technology across the industry to help bring life-saving therapies to patients in need, as well as equipping oncologists with insights to develop targeted treatment programs for their patients."
Leveraging its novel phosphoprotein-based assay, Theralink enables biopharma clients to expedite drug development and ultimately shorten time to market, which can potentially save millions of development dollars, by providing invaluable insights into a drug’s biological impact. Theralink supports its partners across the entire drug development continuum from discovery to clinical market with services including: phosphoproteomic profiling in preclinical models and clinical samples, the evaluation of drug target inhibition within laser capture microdissected tumor samples, and interrogation of compensatory feedback mechanisms and pathways after drug target inhibition.
In addition, the Company is in early discussions with several biopharma companies for the development of Companion Diagnostics. The development of Companion Diagnostics using Theralink’s assays is a potentially large catalyst for Theralink, as well as its biopharma partners, as it is a required test by oncologists to determine a drug’s suitability for their cancer patients.
About Theralink Technologies, Inc.
Theralink Technologies is a proteomics-based, precision medicine company with a CLIA-certified laboratory located in Golden, Colorado. Through its unique and patented phosphoprotein and protein biomarker platform and LDTs, Theralink’s technology targets multiple areas of oncology and drug development. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. Theralink intends to help improve cancer outcomes for patients, help reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit www.theralink.com.
Forward-Looking Statements
Certain statements contained in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, anything relating or referring to future financial results, patient enrollment and plans for future business development activities, and are thus prospective. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified based on current expectations. Such risks and uncertainties include, without limitation, the risks and uncertainties set forth from time to time in reports filed by Theralink Technologies with the Securities and Exchange Commission. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business and although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements contained herein. The company undertakes no obligation to publicly release statements made to reflect events or circumstances after the date hereof.
SOURCE Theralink Technologies
More news releases in similar topics
Cision Distribution 888-776-0942
from 8 AM – 9 PM ET
Author Profile
Latest entries
पंजाब2024.04.20भाजपा महिला मोर्चा प्रदेश कार्यकारणी सदस्य रिंपी शर्मा ने अनीता सोमप्रकाश से की मुलाकात
राशीफल2024.04.20आज का राशिफल : मीन समेत इन 5 राशियों का चमकेगा भाग्य,जाने अपना राशिफल – NW News – Newwaynews24
लाइफस्टाइल2024.04.20अमरीश पुरी से पहले बॉलीवुड के इस खलनायक का खौफ खाते थे लोग, करियर के आखिरी दिनों में चली गई थी आंखों की रोशनी- बता सकते हैं नाम – Head Topics
धर्म2024.04.20रसरंग में मायथोलॉजी: मिथ, मायथोलॉजी और इतिहास में अंतर को रामायण-महाभारत से समझें – Dainik Bhaskar
